LEADER 01396nam  2200349z- 450 
001 9910694354403321
005 20070823084048.0
035   $a(CKB)5860000000017791
035   $a(BIP)017102673
035   $a(EXLCZ)995860000000017791
100   $a20220406c2007uuuu  -u-         -
101 0 $aeng
200 10$aAllegations of waste, fraud, and abuse in pharmaceutical pricing $efinancial impacts on federal health programs and the federal taxpayer : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Tenth Congress, first session, February 9, 2007
215   $a1 online resource (iii, 186 p.) $cill
311   $a0-16-079064-6 
517   $aAllegations of waste, fraud, and abuse in pharmaceutical pricing 
606   $aPrescription pricing$xCorrupt practices$zUnited States
606   $aDrugs$xPrices$zUnited States
606   $aWaste in government spending$zUnited States
610   $aDrugs
610   $aWaste in government spending
610   $aPricing
610   $aMedical
610   $aPolitical science
610   $aBusiness & economics
615  0$aPrescription pricing$xCorrupt practices
615  0$aDrugs$xPrices
615  0$aWaste in government spending
906   $aBOOK
912   $a9910694354403321
996   $aAllegations of waste, fraud, and abuse in pharmaceutical pricing$93198683
997   $aUNINA